COST UTILITY ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE AND DULAGLUTIDE FOR PATIENTS WITH TYPE 2 DIABETES IN SAUDI ARABIA

被引：0
|
作者：
Hassan, M. [1 ]
Barham, L. [2 ]
机构：
[1] Novo Nordisk, Riyadh 01, Saudi Arabia
[2] Univ South Wales, Learna Ltd Partnership, Royston, Hrt, England
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE23
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [21] Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes Response
    Arslanian, Silva A.
    Cox, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (16): : 1530 - 1531
  • [22] Once-weekly semaglutide provides better health outcomes compared to dulaglutide as dual therapy in the treatment of type 2 diabetes: a cost-effectiveness analysis
    Tikkanen, C. K.
    Johansen, P.
    Hunt, B.
    Malkin, S.
    Pollock, R. F.
    DIABETOLOGIA, 2018, 61 : S426 - S427
  • [23] Emerging utility of once-weekly exenatide in patients with type 2 diabetes
    Goud, Aditya
    Zhong, Jixin
    Rajagopalan, Sanjay
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2015, 8 : 505 - 512
  • [24] ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON SUSTAIN 7
    Malkin, S. J.
    Belbute, D. G.
    Hunt, B.
    Hoxer, C. S.
    Martin, V
    VALUE IN HEALTH, 2018, 21 : S129 - S129
  • [25] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
  • [26] Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
    Viljoen, Adie
    Hoxer, Christina S.
    Johansen, Pierre
    Malkin, Samuel
    Hunt, Barnaby
    Bain, Stephen C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 611 - 621
  • [27] Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
    Lingvay, Ildiko
    Benamar, Malik
    Chen, Liming
    Fu, Ariel
    Jodar, Esteban
    Nishida, Tomoyuki
    Riveline, Jean-Pierre
    Yabe, Daisuke
    Zueger, Thomas
    Rea, Rosangela
    DIABETOLOGIA, 2025, : 739 - 751
  • [28] A COST-OF-CONTROL ANALYSIS: ONCE-WEEKLY SEMAGLUTIDE REDUCES COST OF REACHING TREATMENT TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN NORWAY
    Hamidi, V
    Sverre, J. M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [29] Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
    Pratley, R. E.
    Aroda, V. R.
    Gondolf, T.
    Hansen, T.
    Lingvay, I.
    Ludemann, J.
    Skjoth, T. V.
    Viljoen, A.
    DIABETOLOGIA, 2019, 62 : S374 - S374
  • [30] Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
    Petri, Kristin Cecilie Carlsson
    Ingwersen, Steen Hvass
    Flint, Anne
    Zacho, Jeppe
    Overgaard, Rune Viig
    DIABETES THERAPY, 2018, 9 (04) : 1533 - 1547
12345